Drugs / Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04215016 | Dec 2019 → Dec 2023 | relapsed/refractory diffuse large B-cell lymphoma | Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04215016 ↗ |
| Modality | Cell therapy | “CD19 CAR-T cell therapy” NCT04215016 ↗ |